Related Experiment Video
Updated: Mar 27, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
Regulatory T Cell Immunotherapy in Immune-Mediated Diseases
Antonio Pierini1, Dominik Schneidawind2, Hidekazu Nishikii3
1Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, USA; Hematology and Clinical Immunology, Department of Medicine, University of Perugia, Perugia, Italy.
Abstract:
Broad clinical interest rapidly followed the recent discovery of different subpopulations of T cells that have immune regulatory properties and a number of studies have been conducted aiming to dissect the translational potential of these promising cells. In this review we will focus on forkhead box P3 (FoxP3) positive regulatory T cells, T regulatory type 1 cells and invariant natural killer T cells (iNKT). We will analyze their ability to correct immune dysregulation in animal models of immune mediated diseases and we will examine the first clinical approaches where these cells have been directly or indirectly employed. We will discuss successes, challenges and limitations that rose in the road to the clinical use of regulatory T cells.
Related Concept Videos
Tumor Immunotherapy
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Cell-mediated Immune Responses

